Unknown

Dataset Information

0

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

ABSTRACT: Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without the ALK translocation. These results support the dependence of ALK-rearranged tumors on ALK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this soft-tissue tumor. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).

SUBMITTER: Butrynski JE 

PROVIDER: S-EPMC3014292 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no observed activity in another patient witho  ...[more]

Similar Datasets

Unknown CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
| S-EPMC7524717 | biostudies-literature
Unknown Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
| S-EPMC5091324 | biostudies-literature
Unknown Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
| S-EPMC5617123 | biostudies-literature
Unknown ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma.
| S-EPMC5337428 | biostudies-literature
Unknown Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
| S-EPMC3385512 | biostudies-literature
Unknown TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.
| S-EPMC1850130 | biostudies-literature
Unknown Inflammatory Myofibroblastic Tumor of the Upper Airways Harboring a New TRAF3-ALK Fusion Transcript.
| S-EPMC8232338 | biostudies-literature
Unknown EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors.
| S-EPMC6263129 | biostudies-literature
Unknown STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.
| S-EPMC4467062 | biostudies-literature
Unknown Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
| S-EPMC3311875 | biostudies-literature